Study of Serum Pentraxin 3 as a Marker for Predicting Risk of Prostate Cancer.
- rpihefngo
- Mar 19
- 2 min read
Updated: Apr 18
2025, January, Volume 2, Issue 1, Page: 9-13
1) Dr. Amita Gupta, Assistant Professor, Department of Biochemistry, MGM Medical College, Indore (Corresponding Author)
2) Dr. Rajeev Lohokare, Associate Professor, Department of Biochemistry, MGM Medical
College, Indore
3) Dr. P. D. Sarkar, Professor, Department of Biochemistry, MGM Medical College, Indore
4) Dr. Akshatha R, JR, Department of Biochemistry, MGM Medical College, Indore
Abstract:
Introduction: - It is known that prostate cancer is one of the most common malignancies in males worldwide. Prostate biopsy can be considered as gold standard for diagnosis of prostate cancer but the diagnostic yield of a first extended prostate biopsy remains low. Pentraxins are a family of evolutionarily conserved proteins implicated in innate immunity and inflammation. Chronic inflammation has been implicated in prostate carcinogenesis by several mechanisms. Pentraxin 3 seems to be involved in inflammatory-related carcinogenesis and so we thought it worthwhile to test the potential correlation between pentraxin 3 and prostate cancer.
Materials & Methods: A cross sectional study, over a period of 1 year, which included patients scheduled for prostate biopsy at M.Y. Hospital, Indore was conducted. 70 patients were enrolled in the study after taking informed consent. Blood samples were collected and serum pentraxin 3 levels were measured.
Results: Among the subjects, prostate cancer was detected in 44.3% of patients and serum pentraxin 3 levels were significantly higher in those with prostate cancer than those without prostate cancer.
Conclusion: Our study indicated that serum pentraxin 3 levels might be useful biomarker in predicting risk of prostate cancer and hence can be used as a valuable tool for improving prostate cancer screening and patient management strategies.
Key Words: Prostate Cancer, Pentraxin, Inflammation, biomarker